Operating Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Summary of segmental information
Contract/Grant Revenue	$ 2,959,254	$ 3,879,675	$ 8,750,291	$ 5,795,788
Income (Loss) from Operations	(1,498,817)	(1,269,666)	(4,414,479)	(4,862,684)
Amortization and Depreciation Expense	22,466	62,840	67,902	184,496
Other Income (Expense), Net	(174,400)	4,044,014	1,499,055	(909,984)
Share-Based Compensation	117,250	134,924	453,935	414,112
Identifiable Assets	7,753,804		7,753,804		$ 7,387,122
Vaccines/BioDefense [Member]
Summary of segmental information
Contract/Grant Revenue	2,959,254	3,879,675	8,750,291	5,781,816
Income (Loss) from Operations	239,012	653,415	1,291,123	1,040,627
Amortization and Depreciation Expense	10,090	10,093	30,150	29,820
Share-Based Compensation	25,164	19,344	77,393	63,280
Identifiable Assets	1,801,149		1,801,149		2,123,676
BioTherapeutics [Member]
Summary of segmental information
Contract/Grant Revenue				13,972
Income (Loss) from Operations	(908,086)	(959,065)	(2,822,766)	(3,094,883)
Amortization and Depreciation Expense	10,313	50,673	31,309	148,913
Share-Based Compensation	30,496	29,180	96,313	88,615
Identifiable Assets	56,555		56,555		76,183
Corporate [Member]
Summary of segmental information
Income (Loss) from Operations	(829,743)	(964,016)	(2,882,836)	(2,808,428)
Amortization and Depreciation Expense	2,063	2,074	6,443	5,763
Other Income (Expense), Net	(174,400)	4,044,014	1,499,055	(909,984)
Share-Based Compensation	61,590	$ 86,400	280,229	$ 262,217
Identifiable Assets	$ 5,896,100		$ 5,896,100		$ 5,187,263